Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy
Creators
- 1. Tokushima University/Medical Research, Tokushima, Japan; Kanaiso Hospital, Komatsushima, Tokushima, Japan
- 2. Kanaiso Hospital, Komatsushima, Tokushima, Japan
Description
The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.
Files
Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy.pdf
Files
(761.4 kB)
Name | Size | Download all |
---|---|---|
md5:2f870aaaf2b7a6af98c43f96ae1cedd4
|
761.4 kB | Preview Download |